TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP) today announced the voting results from its Annual General Meeting held on June 22, 2017 in Toronto, Ontario. The total number of shares represented in person or by proxy at the meeting was 121,191,442, representing 56.87% of the total issued and outstanding Acerus shares.
Election of Directors
The six (6) candidates nominated for election to the Acerus Board of Directors and listed in the Company's Management Information Circular, dated May 12, 2017, were elected by a majority of the shareholders present in person or represented by proxy at the meeting. The voting results are as follows:
|Name||Votes For (%)||Votes Withheld (%)|
|Norma Beauchamp||117,492,271 (99.64%)||426,630 (0.36%)|
|Borys Chabursky||116,721,171 (98.98%)||1,197,730 (1.02%)|
|Stephen Gregory||116,591,144 (98.87%)||1,327,757 (1.13%)|
|Ian Ihnatowycz||116,598,871 (98.88%)||1,320,030 (1.12%)|
|Luc Mainville||117,471,271 (99.62%)||447,630 (0.38%)|
|Tom Rossi||116,530,144 (98.82%)||1,388,757 (1.18%)|
Appointment of Auditors
Acerus also announced today that its shareholders have approved the re-appointment of PricewaterhouseCoopers LLP as the Auditor of Acerus to hold office until the next annual meeting of shareholders.
Acerus Pharmaceuticals Corporation is a fully-integrated, Canadian specialty pharmaceutical company engaged in the development, manufacture, marketing and distribution of innovative, branded products in Men’s and Women’s Health. Acerus’ shares trade on TSX under the symbol ASP. For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn.